Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 42

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 42
---
 information contained in the tables that follow this discussion. For fiscal year 2024, our named executive officers were:

| Name                      | Position                                                                             |
| AnhCo Nguyen, Ph.D.(1)    | President and Chief Executive Officer                                                |
| Eric Hyllengren(2)        | Former Executive Vice President, Chief Financial Officer and Chief Operating Officer |
| Jill Henrich(3)           | Former Executive Vice President, Chief Regulatory Officer                            |
| Pascal Touchon, D.V.M.(4) | Former President and Chief Executive Officer                                         |
| Amar Murugan(5)           | Former Executive Vice President, Chief Legal Officer                                 |

(1) Dr. Nguyen was promoted to President and Chief Executive Officer in September 2024. (2) Mr. Hyllengren was promoted to Executive Vice President, Chief Financial Officer and Chief Operating Officer in October 2024. Mr. Hyllengren’s employment with the Company ended in March 2025. (3) Ms. Henrich resigned as the Company’s Executive Vice President, Chief Regulatory Officer in March 2025. (4) Dr. Touchon resigned as the Company’s President and Chief Executive Officer in September 2024. (5) Mr. Murugan’s employment with the Company ended in November 2024. While the principal purpose of this CD&A is to discuss the compensation of our named executive officers, many of the programs discussed apply to other members of senior management who, together with the named executive officers, are collectively referred to as our executive officers.

<div align='center'>26</div>

Compensation Practices and Governance Highlights The Human Capital Committee recognizes that we operate in the highly competitive and dynamic biotechnology industry, and in particular, within the cell and gene therapy area. Therefore, in order to provide overall compensation packages to our executive officers that are competitive with the packages offered by companies with which we compete for executive talent, our Human Capital Committee reviews market best practices in executive compensation to continually refine our programs. In addition, our Human Capital Committee reviews our executive compensation program to evaluate whether our practices align the interests of our directors and executive officers with our stockholders. Below are features of our compensation program which the Human Capital Committee believes demonstrate our commitment to link executive compensation to performance and to incentivize the creation of stockholder value.

| Pay-for-Performance Philosophy                | ❖We link a significant proportion of the compensation of our named executive officers to the achievement of pre-established corporate goals and stock price appreciation (through use of